https://www.live-feeds.com/feed/moderna-stock-hits-4-year-high-on-planned-national-cancer-vaccine-effortContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-stock-hits-4-year-high-on-planned-national-cancer-vaccine-efforthttps://www.live-feeds.com/feed/moderna-stock-hits-4-year-high-on-planned-national-cancer-vaccine-effort#u121722Wed, 14 Oct 2026 11:57:14 +0000Moderna shares surged to a four-year high following a New York Times report detailing an initiative to accelerate cancer vaccine development. Investors positioned the mRNA biotechnology firm as a primary beneficiary of the planned national effort. The market reaction reflects heightened expectations for the company's oncology pipeline, which includes a personalized mRNA cancer vaccine evaluated in combination with the immunotherapy Keytruda. The wider biopharmaceutical sector also saw increased attention as markets weighed the impact of government backing for accelerated cancer treatments